206 related articles for article (PubMed ID: 36209300)
1. Insilco and Invitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations.
Abohassan M; Alshahrani M; Alshahrani MY; Rajagopalan P
Med Oncol; 2022 Oct; 39(12):249. PubMed ID: 36209300
[TBL] [Abstract][Full Text] [Related]
2. Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.
Yang C; Chen Y; Wu T; Gao Y; Liu X; Yang Y; Ling Y; Jia Y; Deng M; Wang J; Zhou Y
Eur J Med Chem; 2023 Oct; 258():115543. PubMed ID: 37329712
[TBL] [Abstract][Full Text] [Related]
3. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
Herschbein L; Liesveld JL
Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
[TBL] [Abstract][Full Text] [Related]
4. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
5. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
6. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
Nepstad I; Hatfield KJ; Grønningsæter IS; Reikvam H
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326335
[TBL] [Abstract][Full Text] [Related]
7. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
Brenner AK; Andersson Tvedt TH; Bruserud Ø
Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
[TBL] [Abstract][Full Text] [Related]
8. Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mTOR signaling and suppression of mitochondrial biogenesis.
Tseng CY; Fu YH; Ou DL; Lu JW; Hou HA; Lin LI
Cancer Gene Ther; 2023 Dec; 30(12):1691-1701. PubMed ID: 37821641
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
10. The Effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on the Expression of Immune Checkpoint Ligands in Acute Myeloid Leukemia Cell Line.
Taghiloo S; Norozi S; Asgarian-Omran H
Iran J Allergy Asthma Immunol; 2022 Apr; 21(2):178-188. PubMed ID: 35490271
[TBL] [Abstract][Full Text] [Related]
11. A pyridinesulfonamide derivative FD268 suppresses cell proliferation and induces apoptosis via inhibiting PI3K pathway in acute myeloid leukemia.
Chen Y; Wu T; Yang C; Lu M; Chen Z; Deng M; Jia Y; Yang Y; Liu X; Wang H; Ling Y; Lu L; Zhou Y
PLoS One; 2022; 17(11):e0277893. PubMed ID: 36413544
[TBL] [Abstract][Full Text] [Related]
12. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
[TBL] [Abstract][Full Text] [Related]
13. Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.
Nepstad I; Reikvam H; Brenner AK; Bruserud Ø; Hatfield KJ
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382066
[TBL] [Abstract][Full Text] [Related]
14. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity.
Yang Y; Sun X; Luo L; Peng R; Yang R; Cheng Z; Lv Y; Li H; Tang Q; Zhu W; Qiao D; Xu S
Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300403. PubMed ID: 37840368
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells.
Reikvam H; Nepstad I; Bruserud Ø; Hatfield KJ
Oncotarget; 2013 Jun; 4(6):830-43. PubMed ID: 23919981
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.
Deng L; Jiang L; Lin XH; Tseng KF; Liu Y; Zhang X; Dong RH; Lu ZG; Wang XJ
Acta Pharmacol Sin; 2017 Mar; 38(3):382-391. PubMed ID: 28042875
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
[TBL] [Abstract][Full Text] [Related]
20. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
Singh P; Kumar V; Gupta SK; Kumari G; Verma M
Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
